NCT06680258Phase 3Not yet recruiting

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Study sponsor: Tempest Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-12Estimated
Enrollment · participants740Estimated
Source updated2025-09-03Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview